Fund Holdings — JOHNSON & JOHNSON

Total Portfolio Value:
$555.05M
Total Bought:
$894.6K
Total Sold:
$16.07M
Net Transaction:
-$15.17M
Securities
▲▼
SharesValue
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Protagonist Therapeutics Inc.2,449,1832,449,1830$162.70M$213.91M38.54%+$51.21M
Nanobiotix S.A.ADS(NBTX)5,623,8165,623,8160$106.23M$130.02M23.43%+$23.79M
Rapport Therapeutics, Inc.(RAPP)1,784,5171,784,5170$53.00M$54.14M9.75%+$1.14M
MeiraGTx Holdings plc(MGTX)6,641,0646,641,0640$54.66M$52.80M9.51%-$1.86M
CVRx, Inc.(CVRX)4,103,4304,024,861-78,569$33.11M$28.58M5.15%-$4.54M
Contineum Therapeutics, Inc.CL A(CTNM)1,979,1731,979,1730$23.26M$22.62M4.08%-$633.3K
Legend Biotech CorporationADS(LEGN)814,586814,5860$26.56M$17.71M3.19%-$8.85M
Xencor, Inc.(XNCR)748,062748,0620$8.77M$11.45M2.06%+$2.68M
PROCEPT BioRobotics Corporation(PRCT)357,939357,9390$12.77M$11.26M2.03%-$1.51M
Fate Therapeutics, Inc.(FATE)3,379,0643,379,0640$4.26M$3.32M0.60%-$937.4K
Neumora Therapeutics, Inc.(NMRA)1,849,4451,849,4450$3.37M$3.31M0.60%-$55.5K
Rallybio Corporation(RLYB)3,636,3633,636,3630$1.81M$2.49M0.45%+$680.4K
Lyell Immunopharma, Inc.(LYEL)54,88754,8870$891.4K$1.69M0.30%+$798.1K
Vor Biopharma Inc.(VOR)053,732+53,732$0$702.8K0.13%+$702.8K
Nano-X Imaging Ltd.
ORD SHS
158,852158,8520$587.8K$444.8K0.08%-$143.0K
Standard BioTools Inc.(LAB)311,967311,9670$405.6K$399.3K0.07%-$6.2K
Adicet Bio, Inc.022,779+22,779$0$191.8K0.03%+$191.8K
Adicet Bio, Inc.364,4720-364,472$295.3K$0—-$295.3K
Arrowhead Pharmaceuticals, Inc.(ARWR)247,5980-247,598$8.54M$0—-$8.54M
Tessera Defense and Homeland Security Inc.(HLSQ)96,8660-96,866$50.9K$0—-$50.9K
Senseonics Holdings, Inc.(SENS)54,6210-54,621$23.8K$0—-$23.8K
Vor Biopharma Inc.(VOR)53,7320-53,732$2.62M$0—-$2.62M
Page 1 of 1
JOHNSON & JOHNSON — 13F Holdings — Q4 2025 | TickerTrail